KLab is already marketing some of its patented products .
 
 
KLab has 90% market share of the complete Methocarbamol market in India.
 
KLab is the only company marketing Prenoxdiazine in India.
 

Present

Introduced Patented Products based on NDDS
(Marketed in India and out-Licensed for the Developing Countries)

  

Future

Patents driven by NDDS, Nano and Dendrimers
(To be marketed in India and to be out Licensed to the developed countries)

 
  KLAB is marketing its generic products in the various therapeutic segments through its sales team. KLAB products are manufactured in WHO-GMP facilities. KLAB has contract manufacturing agreement with Indian and International companies for some of their products.
KLab has focus on Chiral synthesis. Chiral synthesis has become important in research and industry due to the pathways increased need for enantiopure chiral durgs. This leads to strong and fast growing range of new chiral building blocks, chiral catalysts and the increased use of chiral biotransformation in organic synthesis. 

  KLab is one of the pioneers in India in KLAB is a pioneer in the Indian Oncology formulations market. It has one of the widest range of Oncology formulations, which are manufactured at KLAB owned WHO-GMP approved facility at Thane, Mumbai.
 
KLAB manufactures tablets, capsules, powder and liquid injectables.
KLAB's oncology products are now registered in more than 30 countries in Africa, Latin America, CIS and South East Asia. In India KLAB has a dedicated Oncology task force which covers Oncologists and Oncology Institutions across the length and breadth of India. Further, KLAB supplies finished ONCO formulations to a large number of Indian Companies.
KLab has a dedicated oncology facility for manufacturing various APIs. KLab also has a separate sterile powder manufacturing facility. 

  KLab is manufacturing these speciality APIs majorly for its own captive consumption.

   
© 2001 - 2007 Khandelwal Laboratories Pvt.Ltd. All rights reserved.